Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 3
1966 3
1968 1
1969 1
1970 2
1971 1
1972 4
1973 2
1974 7
1975 6
1976 4
1977 9
1978 10
1979 19
1980 16
1981 19
1982 15
1983 12
1984 15
1985 6
1986 14
1987 31
1988 41
1989 61
1990 58
1991 70
1992 98
1993 94
1994 103
1995 126
1996 119
1997 120
1998 109
1999 127
2000 137
2001 147
2002 158
2003 137
2004 184
2005 160
2006 186
2007 185
2008 171
2009 199
2010 181
2011 201
2012 219
2013 205
2014 252
2015 247
2016 279
2017 244
2018 243
2019 296
2020 309
2021 313
2022 307
2023 302
2024 324
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

6,400 results

Results by year

Filters applied: . Clear all
Page 1
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, Varricchio S, Casadio P, Inzani F, Seracchioli R, Mollo A, Mascolo M, Zannoni GF. Arciuolo D, et al. Int J Mol Sci. 2022 Oct 2;23(19):11684. doi: 10.3390/ijms231911684. Int J Mol Sci. 2022. PMID: 36232987 Free PMC article. Review.
The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), i.e., POLE-mutant, mismatch repair (MMR)-deficient, p53-abnormal, and "no specific molecular profile" (NSMP), have recently been integrated into ESGO-ESTRO-ESP guidelines. ...
The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), i.e., POLE-mutant, mismatch repair (MMR)-defici …
Molecular Genetics of Endometrial Carcinoma.
Bell DW, Ellenson LH. Bell DW, et al. Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Annu Rev Pathol. 2019. PMID: 30332563 Review.
Endometrioid endometrial carcinomas constitute approximately 85% of newly diagnosed cases; serous carcinomas represent approximately 3-10% of diagnoses; clear cell carcinoma accounts for <5% of diagnoses; and uterine carcinosarcomas are rare, biphasic tumors. ... …
Endometrioid endometrial carcinomas constitute approximately 85% of newly diagnosed cases; serous carcinomas represent approximately …
Incorporation of molecular characteristics into endometrial cancer management.
Vermij L, Smit V, Nout R, Bosse T. Vermij L, et al. Histopathology. 2020 Jan;76(1):52-63. doi: 10.1111/his.14015. Histopathology. 2020. PMID: 31846532 Free PMC article. Review.
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. This provides clinicians with prognostic information and input for further treatment recommendations. Nonetheless, patients with histological …
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. T …
FIGO 2023 endometrial cancer staging: too much, too soon?
McCluggage WG, Bosse T, Gilks CB, Howitt BE, McAlpine JN, Nucci MR, Rabban JT, Singh N, Talia KL, Parra-Herran C. McCluggage WG, et al. Int J Gynecol Cancer. 2024 Jan 5;34(1):138-143. doi: 10.1136/ijgc-2023-004981. Int J Gynecol Cancer. 2024. PMID: 37935523 Review.
An updated International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma was introduced in June 2023. The new system represents a significant departure from traditional endometrial and other gynecological carcinoma
An updated International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma was introduce …
Clear cell carcinoma of the endometrium.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Gynecol Oncol. 2022 Mar;164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063279 Review.
Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or …
Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to su …
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, González-Martín A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X. Concin N, et al. Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z. Virchows Arch. 2021. PMID: 33604759 Free article.
A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, …
A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelin …
Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis.
Huvila J, Pors J, Thompson EF, Gilks CB. Huvila J, et al. J Pathol. 2021 Apr;253(4):355-365. doi: 10.1002/path.5608. Epub 2021 Feb 6. J Pathol. 2021. PMID: 33368243 Review.
Endometrial carcinoma (EC) is classified into a wide range of morphological variants; this list has expanded over the past decade with the inclusion of mesonephric-like and dedifferentiated carcinoma as EC variants in the fifth edition of the WHO Classificati
Endometrial carcinoma (EC) is classified into a wide range of morphological variants; this list has expanded over the past dec
Classification of endometrial carcinoma: more than two types.
Murali R, Soslow RA, Weigelt B. Murali R, et al. Lancet Oncol. 2014 Jun;15(7):e268-78. doi: 10.1016/S1470-2045(13)70591-6. Lancet Oncol. 2014. PMID: 24872110 Review.
Endometrial cancer is the most common gynaecological malignancy in Europe and North America. Traditional classification of endometrial carcinoma is based either on clinical and endocrine features (eg, types I and II) or on histopathological characteristics (e
Endometrial cancer is the most common gynaecological malignancy in Europe and North America. Traditional classification of endomet
Update in the molecular classification of endometrial carcinoma.
Léon-Castillo A. Léon-Castillo A. Int J Gynecol Cancer. 2023 Mar 6;33(3):333-342. doi: 10.1136/ijgc-2022-003772. Int J Gynecol Cancer. 2023. PMID: 36878561 Review.
However, this classification system does not fully reflect the biological diversity of endometrial carcinomas and has limited reproducibility. In the last decade, several studies have reported the strong prognostic value of the molecular endometrial carcinoma
However, this classification system does not fully reflect the biological diversity of endometrial carcinomas and has limited reprodu …
Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.
Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Köbel M, et al. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S123-S131. doi: 10.1097/PGP.0000000000000488. Int J Gynecol Pathol. 2019. PMID: 29517499 Free PMC article. Review.
P53 immunohistochemistry has evolved into an accurate surrogate reflecting the underlying TP53 mutation status of a tumor, and has utility in the diagnostic workup of endometrial carcinomas. Recent work predominantly carried out in tubo-ovarian high-grade serous carcino
P53 immunohistochemistry has evolved into an accurate surrogate reflecting the underlying TP53 mutation status of a tumor, and has utility i …
6,400 results